November 14, 2024 — Qingdao Baheal Medical INC. (“Baheal Medical”, stock code: 301015.SZ) announced that its wholly-owned subsidiary, Beijing Baheal ZHIHE Medical Achievement Transformation Service Co., Ltd., has signed a marketing cooperation agreement with Beijing Biostar Biopharmaceutical Co., Ltd. (“Biostar”, stock code: 2563.HK). Under the agreement, Baheal Medical will obtain exclusive marketing rights in mainland China for Biostar’s independently developed Class 1 innovative drug, Utidelone Injection (brand name: UTIDE®). Baheal Medical will make a non-refundable upfront payment of RMB 50 million to Biostar, and additional milestone payments based on development and sales progress. In return, Biostar will pay Baheal Pharma a tiered promotion service fee based on annual terminal sales.

Tarcine BioMed, a subsidiary of Baheal Pharma Group, has announced that its independently developed EB Virus Rta Protein IgG Antibody Detection Kit (Chemiluminescent Immunoassay) has been approved by the National Medical Products Administration. This third-generation diagnostic kit for nasopharyngeal cancer, based on a fully automated magnetic particle chemiluminescence platform, offers more stable results and meets diverse clinical diagnostic needs.

On October 26, 2024, the Second Annual Conference of the National Infectious Disease Medical Center's Infectious Disease Specialty Alliance was held in Kunming, Yunnan. During the event, a strategic cooperation agreement was signed between Baheal Pharma and the National Infectious Disease Medical Center (Beijing) and Beijing Ditan Hospital. This partnership aims to address major national needs in infectious disease prevention and treatment, focusing on technology innovation, result transformation, and talent cultivation. Attending the signing ceremony were Jin Ronghua, Director of the National Center for Infectious Diseases (Beijing) and President of Beijing Ditan Hospital; Chen Xiaoyou, Executive Vice President of Beijing Ditan Hospital; Yang Zhiyun, Vice President; Tian Xin, Deputy Secretary; Li Xin, Director of the Science and Technology Department; Song Qing, Director and President of Baiyang Pharmaceutical Group; Wang Biquan, Vice President of Innovative Drugs and Devices; and Zhang Shuying, Strategic Customer Director.

Recently, the winners of two highly anticipated awards in the domestic capital market — the "Most Valuable Listed Company Golden Bull Award" and the "China Listed Company Value Awards" — were announced. Baheal Medical (301015.SZ) stood out among thousands of listed companies, winning the titles of "Most Valuable Investment Golden Bull Award 2023" and "Top 50 GEM Listed Companies by Value." These accolades highlight the capital market's strong recognition of the company's exceptional performance, value return capabilities, and growth potential.

On September 27, 2024, Xuanwu Hospital of Capital Medical University held its 2024 Medical Education and Research Conference. During the event, Baheal Pharma Group and Xuanwu Hospital signed a strategic cooperation agreement to jointly establish the "Xuanwu-Baheal Pharma Neurological Disease Collaborative Innovation Laboratory" and the "Xuanwu-Baheal Pharma Thoracic Disease Joint Laboratory." The collaboration aims to advance cutting-edge medical research and the translation of scientific achievements in key areas such as neuroscience and thoracic surgery. The signing ceremony was attended by Guan Zhongjun, Party Secretary of Xuanwu Hospital, Zhao Guoguang, Deputy Party Secretary and President of Xuanwu Hospital, Fu Gang, Chairman of Baheal Pharma Group, and Song Qing, Director and President of Baheal Pharma Group.